SCHEMBL344528

SCHEMBL344528

COC(=O)c1cccc2cccnc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.65
PARP1 P09874 1/20 0.62
SLC40A1 Q9NP59 1/20 0.61
KDM4E B2RXH2 3/20 0.56
RAB9A P51151 2/20 0.56
NPC1 O15118 2/20 0.56
CASP3 P42574 1/20 0.56
SENP8 Q96LD8 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
TDP1 Q9NUW8 2/20 0.53
EGLN1 Q9GZT9 1/20 0.51
LMNA P02545 2/20 0.50
HDAC8 Q9BY41 1/20 0.50
PSMD14 O00487 1/20 0.50
MAP2K1 Q02750 1/20 0.50
ALOX15 P16050 1/20 0.50
HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28624165 0.85 ALDH1A1 (0.58) ALDH1A1PARP1SLC40A1KDM4ERAB9A
SCHEMBL3441534 0.84 ALDH1A1 (0.67) ALDH1A1PARP1SLC40A1KDM4ERAB9A
SCHEMBL28229068 0.83 ALDH1A1 (0.65) ALDH1A1PARP1SLC40A1KDM4ERAB9A
SCHEMBL9944361 0.82 ALDH1A1 (0.60) ALDH1A1PARP1SLC40A1KDM4ERAB9A
SCHEMBL27872895 0.82 ALDH1A1 (0.60) ALDH1A1PARP1SLC40A1KDM4ERAB9A
SCHEMBL6822984 0.82 ALDH1A1 (0.60) ALDH1A1PARP1KDM4ERAB9ANPC1
SCHEMBL8139304 0.82 KDM4E (0.56) ALDH1A1PARP1SLC40A1KDM4ETDP1
SCHEMBL244112 0.82 EGLN1 (0.68) ALDH1A1KDM4EEGLN1
SCHEMBL3502575 0.82 KDM4E (0.56) ALDH1A1SLC40A1KDM4ERAB9ANPC1
SCHEMBL25108830 0.81 PARP1 (0.55) ALDH1A1PARP1SLC40A1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004072046-A2 QUINOLINE DERIVATIVES AND THEIR USE FOR MODULATION OF LXR ACTIVITY CAREX S.A. (FR) 2004-08-26 WO claimed
US-3959473-A DIURETIC U.S. PHILIPS CORPORATION (US) 1976-05-25 US claimed
WO-2025119326-A1 NOVEL PRMT5 INHIBITOR AND USE THEREOF 上海湃隆生物科技有限公司 2025-06-12 WO disclosed
CN-115232144-B Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof 长春金赛药业有限责任公司 2024-04-02 CN disclosed
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 CN disclosed
CN-117362323-A PRMT5 inhibitor and application thereof 上海赛岚生物科技有限公司 2024-01-09 CN disclosed
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS UNIVERSITY OF OULU (FI) 2023-10-12 US disclosed
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS UNIVERSITY OF OULU (FI) 2023-10-12 US disclosed
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS UNIVERSITY OF OULU (FI) 2023-10-12 US disclosed
EP-3704113-B1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-10-11 EP disclosed
EP-3704113-B1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-10-11 EP disclosed
EP-1192137-A1 COMPOUNDS FOR THE MODULATION OF PPAR$g(g) ACTIVITY Tularik Inc. (US) 2002-04-03 EP disclosed
WO-2002000633-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS TULARIK INC. (US) 2002-01-03 WO disclosed
WO-2001000579-A1 COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY TULARIK INC. (US) 2001-01-04 WO disclosed
CN-1175247-A Steroid receptor modulator compounds and methods LIGAND PHARM INC (US) 1998-03-04 CN disclosed
EP-0758333-A1 INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION GLAXO WELLCOME INC. (US) 1997-02-19 EP disclosed
WO-1995029917-A2 INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION GLAXO WELLCOME INC. (US) 1995-11-09 WO disclosed
US-4968803-A FLUORINE AS OXIDANT ALLIED-SIGNAL INC. (US) 1990-11-06 US disclosed
US-4832731-A Quinoline-8-carboxylic acid azolides and their use as herbicides BASF AKTIENGESELLSCHAFT (DE) 1989-05-23 US disclosed
US-3959473-A DIURETIC U.S. PHILIPS CORPORATION (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS CBR3, GBA3, TECR ALDH1A1 2476/4885PARP1 1472/4885SLC40A1 3465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.